John Overdeck’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

John Overdeck’s Portfolio TPTX Stock Details TPTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-201,558	Closed	-$5.41M	–	3133
2022 Q1	$5.41M	Buy	201,558 +190,569	+1,734%	+$6.4M	0.02%	882
2021 Q4	$524K	Sell	10,989 -17,992	-62%	-$804K	﹤0.01%	3210
2021 Q3	$1.93M	Sell	28,981 -116,799	-80%	-$8.32M	﹤0.01%	2031
2021 Q2	$11.4M	Sell	145,780 -42,924	-23%	-$3.17M	0.03%	723
2021 Q1	$17.9M	Buy	188,704 +100,159	+113%	+$11.9M	0.05%	484
2020 Q4	$10.8M	Buy	88,545 +38,523	+77%	+$4.22M	0.03%	564
2020 Q3	$4.37M	Sell	50,022 -30,903	-38%	-$2.15M	0.02%	860
2020 Q2	$5.23M	Buy	+80,925	New	+$4.67M	0.03%	628

Other funds holding TPTX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

John Overdeck's TPTX Position: Q2 2022 in Review

John Overdeck sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q2 2022, closing a stake of 201,558 shares — an estimated $5.41M sold.

John Overdeck first reported a position in TPTX in Q2 2020 and held it in 8 quarters. The position peaked at $17.9M in Q1 2021. 208 funds tracked by Wall St. Rank hold TPTX as of Q2 2022.

John Overdeck reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
John Overdeck sold 201,558 Turning Point Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $5.41M.
John Overdeck first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q2 2020 and held it in 8 quarters.
John Overdeck's Turning Point Therapeutics, Inc. Common Stock position peaked at $17.9M in Q1 2021.
208 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q2 2022.

Based on Two Sigma Investments's 13F filing for Q2 2022, filed 15 Aug 2022.